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INTRODUCTION 
 Direct compression (DC) is the simplest means of production of a 
pharmaceutical tablet. It requires only that the active ingredient is accurately blended 
with suitable excipients previous to compression. A part from the simplicity of 
formulation and manufacture, the key in advantages of direct compression contain 
reduced capital, labor, and force costs for manufacture and the escaping of water for 
granulation for water responsive drug substances. This guide describes the scope and 
first principles involved in the formulation of tablets by direct compression. The most 
observable part in determining whether DC is related to a certain drug substance is 
dose. Three key factors for successful tab letting are flow and the compressed facility of 
the compression mix up, and drug content uniformity in the blend and the final tablets. 
All of these factors are likely to be affect by drug dose. In this lead, a low dose is in use 
to mean 10 mg or lower, the medium dose is taken to mean 10 mg to 50 mg and high 
dose is taken to mean above 50mg.For low dose drugs, flow and compaction of the 
compression mix are largely confer by the excipients and the primary concern is likely to 
getting of good content uniformity in the blend and in the tablets. For medium dose 
drugs flow of the compression mix may become a vital factor, and for high dose drugs 
the flow and compaction are highly dependent on the property of the drug substance [1] 
  
Advantages and Disadvantages Of Direct Compression: 
Advantages 
• Fewer stability issues for actives that are sensitive to heat or moisture 
• For certain compounds, faster dissolution rates may be generated from tablets 
prepared by direct compression compared with wet granulation; for example, 
norfloxacin 
• Fewer excipients may be needed in a direct compression formula 
Disadvantages 
• Issues with segregation – these can be reduced by matching the particle size and 
density of the active drug substance with excipients 
• In general, the drug content is limited to approximately 30% or approximately50 mg 
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• May not be applicable for materials possessing a low bulk density since after 
compression the tablets produced may be too thin 
• Not proper for poorly flowing drug compounds 
• Static charge may develop on the drug particles or excipients during mixing, which can 
guide to agglomeration of particle produce poor mixing 
 
Direct Compression Excipients 
Although the principles leading direct compression have been well known for 
many years, the method has only recently grown to be more establish as a result of the 
introduction of excipients specially designed for direct compression. These excipients 
are not only directly compressible themselves, but can also be mix with a large 
proportion of drug substance with no major corrosion in tablet quality. In  to excipients 
possessing good flow and compression property, they must also possess the following 
attributes 
• Particle size distributions to are similar to most active drug substances, thus avoid 
separation during processing 
• A high bulk density; 
• The batch-to-batch value must be reproducible. These attributes are the most 
dangerous for direct compression functionality. The remaining attribute are necessary 
for all excipients 
• Physically and chemically constant when in getting in touch with moisture, air and heat 
• Chemically inert; do not enhance the degradation of active ingredients or other 
excipients 
• Compatible with covering works 
• Available international, and rather from more than one supplier. 
  For example, microcrystalline cellulose can be used as an anti-adherent (5–
20%), a disintegrant (5–15%) and the same as diluents (20–90%). material that is 
currently available as direct compression vehicles can be classified according to their 
fail with flow property 
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Disintegrant and Poor Flow of Microcrystalline Cellulose 
Microcrystalline cellulose is a purify partially depolymerized cellulose, which is 
ready by treat a-cellulose with mineral acids, produce bundles of needle-like 
microcrystal. In expressions of appearance, this excipient is a white, crystalline powder 
composed of agglomerated porous particles. In a survey conduct by the pharmaceutical 
industry, Shang raw and Demarest finished that several formulation scientists rank 
microcrystalline cellulose as the majority useful filler for direct compression. Its regard 
can be credited to its excellent compactibility at low pressures, high dilution possible 
and greater disintegration properties. Eg; paracetamol and potassium phenethicillin as 
model compounds. 
 
Starch 1500 
Local starches cling to good compression individuality, except their poor flow 
properties and far above the ground lubricant sensitivity perform construct them a 
smaller amount suitable for use in direct compression. They are mostly useful as a 
result of their good binding and disintegrant properties. Nevertheless, Starch 1500 
continues to be widely regarded as the after that choice excipient before lactose and 
microcrystalline cellulose. Starch 1500 is a form of pregelatinized starch that has been 
modified to create it extra compressible and flow able in character. In conditions of look, 
it is a white to an off-white powder of a more or less coarse-to-fine nature. It is odorless 
but is report to have a unique taste. During the manufacturing process, a little of the 
hydrogen bonding among amylose and amylopectin is partially rupture, so that the 
product contain 5% free amylose, 15% free amylopectin and 80% unchanged starch. 
The free amylose is dependable for the disintegration property and the free amylopectin 
provides cold water solubility and aids the binding property. Starch 1500 is very 
sensitive to the softening property of alkaline separate lubricants. For this reason, the 
use of magnesium stearate is supposed to be avoided or kept at a level below 0.5% 
since higher concentration can have adverse effects on tablet strength and dissolution. 
Consequently, stearic acid is typically preferred as the lubricant to be used with 
pregelatinized starch. Starch is a good disintegrant but this property may cause longer-
term problems because the compacts formed may be friable. At high strain rates during 
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compression, a large amount of the bend is a stretch and therefore, extend recovery 
occurs during the act of exclusion, remind cap. 
The Sedem expert system is a methodology which is useful in preformulation and 
formulation study of medicines mostly in solid dosage forms. This system inform on the 
physical shape of powdered substances (APIs and excipients) used to formulate 
drugs.[2] By influential whether powders (API or excipients) are proper used for direct 
compression, the SeDeM summary will inform about the advantages and gap of that 
powdered substance to be used in direct compression, so the system inform on whether 
the direct compression method is suitable (e.g.. wet granulation should be applied 
before compression).This novel method is based on the selection and application of 
some parameters that the formulation should fulfill to make sure a booming tablet 
elaborate by direct compression. The following principle is applied 
 
Parameters Examined By the SeDeM Method: 
 SeDeM uses 12 tests [3] to examine whether a powder is suitable for direct 
compression.  
•  Bulk density (Da)  
•  Tapped density (Dc) 
•  Inter-particle porosity (Ie) 
•  Carr index (IC) 
•  Cohesion index(Icd) 
•  Hausner ratio(IH) 
•  Angle of repose(α) 
•  Flowability (t″) 
•  Loss on drying (%HR) 
•  Hygroscopicity (%H) 
•  Particle size (%Pf) 
•  Homogeneity index (Iθ) 
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These tests are grouped into five factors on the basis of the physical 
characteristics of the powder and the functionality of the drug: 
 Dimensional Parameter 
 Compressibility Parameter 
 Flow ability/Powder Flow Parameter 
 Lubricity/Stability Parameter 
 Lubricity/Dosage parameter. 
Table no: 1.1 these tests are grouped into five factors on the basis of the physical 
characteristics of the powder and the equation: 
 
INCIDENCE 
FACTOR 
PARAMETER SYMBOL UNIT EQUATION 
 
Dimension 
Bulk Density Da g/ml Da = P/Va 
Tapped Density Dc g/ml Dc = P/Vc 
 
Compressibility 
Inter-particle 
Porosity 
Ie - Ie = Dc − 
Da/Dc × Da 
Carr Index IC % IC = (Dc − 
Da/Dc) 100 
Cohesion Index Icd N Experimental 
Flowability/Powder 
Flow 
Hausner Ratio IH - IH = Dc/Da 
Angle of 
Repose 
(α) ° tg α = h/r 
Powder Flow t″ s Experimental 
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 The SeDeM method is also a helpful device for the study of the reproducibility of 
a manufacturing method used for a powdered substance and, therefore of the validation 
of systematic variation in explanation. A manufacturing process gives increase to 
variations in the last product and these variations should fall within limits or traditional 
specifications, by applying the SeDeM method to study reproducibility involving batch of 
the same API or excipient, specifications in the different parameters can be established 
to make assured the same quality of the product regardless of the batch analyze. In 
adding up, these specifications must be used for the establishment of particular limits 
for value manages the application. To achieve this target it is necessary to study the 
parameters of the SeDeM Diagram, applying the similar statistic analyses required to 
set up the SeDeM Diagram: A New Expert System for the Formulation of Drugs in Solid 
Form 31 pharmaco technical uniformity between batches. Correct reproducibility 
between batches will ensure the reproducibility and the worth of the tablets formulated 
with this API or excipient, apart from of the batch used. SeDeM Diagrams of three 
batches from the same API, In this case, the mark and the index were very similar. This 
control has the advantage that the procedure has the capacity to detect variations in 
particle size between batches of the product. This ability, in consequence, contributes to 
the formulation of the pharmaceutical forms and their correct dissolution the formulation 
must be representative and appropriate for the supplies of compression technology. The 
implementation of the experimental methodology and calculus must be willingly 
relevant. 
                   
Lubricity/Stability Loss on Drying %HR % Experimental 
Hygroscopicity %H % Experimental 
Lubricity/Dosage Particles < 50 
μm 
%Pf % Experimental 
Homogeneity 
Index 
(Iθ) - * Iθ = Fm / 100 
+ Δ Fmn 
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The SeDeM diagram is a novel and reproducible method for application to 
preformulation studies of tablets [4]. The suitability of a powder (active or inactive 
pharmaceutical ingredient) for direct compression can be studied using this method. 
Moreover, this method can be seen as a useful tool for studying the reproducibility of a 
method used for the preparation of powdered substance. Certain powder characteristic 
parameters are taken into concern for the development of SeDeM diagram. These 
selected parameters are consequently studied and analyze statistically to determine the 
applicability of the method. Also, to ensure reproducible powder quality, suitable 
specifications are recognized for different classification parameters. These 
specifications should also be used to set an acceptable range for each parameter 
adopted in unity with the SeDeM method, with the aim of providing valid specifications 
for any powder substance concerning its suitability for direct compression (5, 6).The 
SeDeM method is based on the experimental study and quantitative determination of 
the characterization parameters of powdered substances that provide the necessary 
information about the ability of a substance to be used for direct-compression 
technology. These 12 parameters were determined by validated experimental methods 
and processed for fitting into SeDeM diagram method and analyze for studying the 
suitability of the powder for direct compression. Thus, SeDeM diagram method could be 
described as a mathematical and graphical representation of powder point parameters 
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for learning direct compression appropriateness of different active and inactive 
ingredients 
 
Determination of acceptable limit values for each parameter included by the 
SeDeM method: 
have achieved the values as described more than, certain limits are set on the 
basis of the parameters selected and the values described in the exercise manual of 
Pharmaceutical Excipients or alternatively on the center of experimental tests. 
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S NO. 
 
INCIDENCE 
 
PARAMETER 
 
ACCEPTABLE 
RANGE 
1 
 
 
Dimension Bulk density 0–1 g/ml 
Tapped density 0-1 g/ml 
2 
 
 
Compressibility Inter-particle porosity 0–1.2 
Carr index 0–50 (%) 
Cohesion index 0–200 (N) 
3 
 
 
Flow ability/powder flow Hausner ratio 3–1 
Angle of repose 50–0 (°) 
Powder flow 20–0 (s) 
4 
 
 
Lubricity/stability Loss on drying 0-10 (%) 
Hygroscopicity 20–0 (%) 
 
5 
Lubricity/dosage Particles < 50 μ 50–0 (%) 
Homogeneity index 0–2 × 10−2 
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LITERATURE REVIEW 
 
Josep M. Sune-Negre, et al, Analyzed Application of the new SeDeM Method is 
proposed for the study of the galenic properties of excipients in terms of the applicability 
of direct-compression technology. Through experimental studies of the parameters of 
the SeDeM Method and their subsequent mathematical treatment and graphical 
expression (SeDeM Diagram), six different DC diluents were analyzed to determine 
whether they were suitable for direct compression (DC). Based on the properties of 
these diluents, a mathematical equation was established to identify the best DC diluents 
and the optimum amount to be used when defining a suitable formula for direct 
compression, depending on the SeDeM properties of the active pharmaceutical 
ingredient (API) to be used. The results obtained confirm that the SeDeM Method is an 
appropriate system, effective tool for determining a viable formulation for tablets 
prepared by direct compression, and can thus be used as the basis for the relevant 
pharmaceutical development. [8] 
 
Johnny Edward Aguilar-Dıaz et al, Studied the SeDeM expert system is based 
on the experimental study and quantitativedetermination of the characterization 
parameters of powdered substances, the aim being to determine whether a substance 
is suitable for producing tablets by means of direct compression (DC) technology, 
thereby reducing the lead time for pre-formulation studies. Additionally, this expert 
system also provides formulations with a minimum number of excipients.We used this 
system to analyze suitable formulas for the production of oro dispersible Ibuprofen 
tablets. Twenty-one disintegrants and ibuprofen were characterized using SeDeM 
methodology. The results indicated that production of ibuprofen tablets by DC would 
require improvements in the dimension and compressibility factors of the active 
pharmaceutical ingredient. The expert system analysis provided the specific percentage 
of disintegrant needed to blend with ibuprofen and a standardized formula of lubricants 
in order to obtain a powder mix that would successfully produce tablets by DC. The 
eight formulas proposed by SeDeM were produced and tested in the laboratory. All 
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eight formulas successfully produced tablets by DC, but only four of them could be 
considered suitable for use as an orodispersible tablet and accomplishes all the 
pharmaceutical quality parameters. So, in fact, the use of the SeDeM system reduced 
the time of medicine’s development and therefore the cost of the activity. [9]  
 
Johnny Edward Aguilar-Díaz, et al, examined the new SeDeM Diagram expert 
system was used to analyze the suitability of 43 excipients for direct compression with 
disintegrating properties from eight chemical families. The SeDeM Diagram expert 
system is a new method for use in tablet preformulation and formulation studies. It 
provides the profile of a substance in powder form in terms of its suitability for direct 
compression. This study was based on the current concept ‘‘Quality by Design ICH Q8”. 
In this the pharmacotechnicalproperties of disintegrants were evaluated in powder form 
and selected the candidates that were most suitable for direct compression and their 
use in the formulation of orally disintegrating tablets (ODT). To achieve this, each 
disintegrant and its chemical families were individually analyzed. It was concluded that 
nine disintegrants had a SeDeM value with the index of good compression (IGC) over 5. 
Most of these disintegrants were from the micro cellulose family. Other disintegrants 
had indexes that were close to 5. It is assumed that these excipients can be used in 
direct compression when they are added to other excipients. [10] 
 Josep M. Suñé-Negre, et al, performed as a methodology for characterizing 
substances in relation to their viability in direct compression, the SeDeM Diagram 
Expert System may be considered an open system in terms of the number of 
parameters applied and the optimization of these parameters. With the experience 
acquired from applying the SeDeM Diagram, in this study, we propose optimizing the 
parameters corresponding to the Hausner index (IH) and relative humidity (%HR) in 
order to simplify the mathematical calculation, so that it provides reliable data that can 
be extrapolated. The proposed optimization does not involve a conceptual change in the 
parameters considered nor did a significant change in the results obtained to compare 
with the previous calculation methodology initially established for the SeDeM Diagram 
Expert System, which means that the conclusions obtained by applying this method are 
equivalent. [11] 
LITERATURE REVIEW 
 
Department Of Pharmaceutics 
Arulmigu Kalasalingam College Of Pharmacy  Page 12 
 
 Johnny Edward Aguilar, et al, evaluated SeDeM-ODT expert system is an 
innovative tool for predicting whether or not an excipient or mixture of powders 
containing API and excipients is suitable to obtain a buccal dispersible tablet by direct 
compression. This preformulation tool identified as the index of good compressibility 
and Oro dispersibility (IGCB index), unique to each powder or mixture of powders and 
based on the SeDeM expert system. The IGCB index indicates if a mixture of powder 
can be compressed by direct compression and, at the same time, indicates if the 
resulting tablets would be suitable for use as orodispersible tablets. SeDeM ODT and 
SeDeM expert systems are excellent tools to optimize tablet fabrication. These tools 
allow a reduction in the number of unnecessary experiments in the laboratory because 
they provide information on rheology, compatibility properties, etc. In addition, these 
tools also provide information that can be used for a better understanding of the 
formulation design. [12]  
 
Sherine S. Diab,e tal prepared Spectrophotometric methods for simultaneous 
determination of a ternary mixture of amlodipine besylate, olmesartanmedoxomil, and 
hydrochlorothiazide. Four, accurate, precise, and sensitive spectrophotometric methods 
are developed for the simultaneous determination of a ternary mixture amlodipine 
besylate (AM), olmesartan medoxomil (OL) and hydrochlorothiazide (HZ), where AM is 
determined at its  ʎ max 364.6 nm (0D), while (OL) and (HZ) are determined by different 
methods. Method (A) depends on determining OL and HZ by measuring the second 
derivative of the ratio spectra (2DD) at 254.4 and 338.6 nm, respectively. Method (B) is 
first derivative of the double divisor ratio spectra (D-1DD) at 260.4 and 273.0 nm for OL 
and HZ, respectively. Method (C) based on successive spectrophotometric resolution 
technique (SSRT). The technique starts with the ratio subtraction method then 
measuring OL and HZ at their isoabsorption point at 260.0 nm, while HZ is measured 
using the amplitude of the first derivative at 335.2 nm. Method (D) is mean centering of 
the ratio spectra (MCR) at 252.0 nm and 220.0 nm for OL and HZ, respectively. The 
specificity of the developed methods is investigated by analyzing laboratory prepared 
mixtures containing different ratios of the three drugs and their combined dosage 
form.The obtained results are statistically compared with those obtained by the official 
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or reported methods, showing no significant difference with respect to accuracy and 
precision at p = 0.05.[14]  
Bindi N. Vora et al, performed Development and validation of the simultaneous 
UV spectrophotometric method for estimation of metoprolol succinate and olmesartan 
medoxomil in the tablet dosage form. The linearity was obtained in the concentration 
range of5–25 μg/ml and 4–20 μg/ml for METO and OLME, respectively. The 
concentrations of the drugs were determined by using the simultaneous equations 
method. The mean recovery was 100.90 ± 1.76 and 100.26 ± 0.71 for METO and 
OLME, respectively. The method was found to be simple, accurate, and precise and 
was applicable for the simultaneous determination of METO and OLME in the 
pharmaceutical tablet dosage form. The results of analysis have been validated 
statistically and by recovery studies. [15] 
Anjali Patel et al, carried out the development of the UV spectrophotometric 
method of Olmesartanmedoxomil in bulk drug and pharmaceutical formulation and 
stress degradation studies. A simple, sensitive, specific, spectrophotometric method 
was developed for the detection of Olmesartanmedoxomil (OLM) in bulk and 
pharmaceutical formulations. The optimum conditions for the analysis of the drug were 
established. OLM was subjected to stress degradation under different conditions 
recommended by the International Conference on Harmonization (ICH). The samples 
so generated were used for degradation studies using the developed method. The λmax 
of the OLM was found to be 257 nm. The method exhibited high sensitivity, with 
linearity, in the 2 to 20 μg/ml range. The lower limit of detection and the limit of 
quantification were found to be 1.012 μg/ml and 3.036 μg/ ml, respectively. All the 
calibration curves demonstrated a linear relationship between the absorbance and 
concentration, with the correlation coefficient higher than 0.99. The regression equation 
of the curve was Y = 0.0579x + 0.0006. The precision of the method was found to be 
40.043 ± 0.067 against the label claim of 40 mg. The percentage recovery was found to 
be 101.32 ± 0.452. The sample solution was stable for up to two hours. Hence, it could 
be concluded that the proposed method would be suitable for the analysis of OLM in 
bulk and pharmaceutical formulations. [16] 
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Kun-Yan Li, et al, performed the Relative Bioavailability and Fasting 
Pharmacokinetics of Three Formulations of OlmesartanMedoxomil 20-mg Capsules and 
Tablets in Healthy Chinese Male Volunteers: An OpenLabel, Randomized-Sequence, 
Single-Dose, Three-Way Crossover Study, Twenty-one healthy male subjects (mean 
age, 21 years [range, 18-25 years]; weight, 62.1 kg [range, 54.0-80.0 kg]) were enrolled 
in and completed the study. No period or sequence effect was observed. The mean 
AUCo_=values for the test tablet, test capsule, and reference tablet were 3993 
(1070),3567 (850), and 3849 (872) ng/mLlh, respectively. The 90% CIs for the log-
transformed ratios of test tablet to reference tablet for Cmax' AUC0-48' and AUCo~ 
were 103.9 to 124.9, 94.0 to 111.5, and 94.4 to 111. 7, respectively (all, P = NS).The 
corresponding 90% CIs for the log-transformed ratios of test capsule to reference tablet 
were 90.8 to  109.2,84.9 to 107.9, and 85.1 to 100.7 (all, P = NS). Ten adverse events 
were reported during the study;7 subjects complained of pain during blood sampling, 
and 3 had a blocked venous catheter. No treatment-related adverse events were 
reported or observed. In this single-dose crossover study in healthy Chinese male 
volunteers, the test and reference formulations of olmesartanmedoxomil20-mg capsules 
and tablets met the regulatory criteria for assuming bioequivalence [17] 
Steven G. Chrysanth al, have done an Evaluation of Antihypertensive Therapy 
with the Combination of OlmesartanMedoxomil and Hydrochlorothiazide. 
Olmesartanmedoxomil plus HCTZ produced greater reductions in both SeDBP and 
seated systolic blood pressure (SeSBP) at week 8 than did monotherapy with either 
component. All olmesartanmedoxomil/HCTZ combinations significantly reduced SeDBP 
and SeSBPcompared with placebo in a dose-dependent manner. Reductions from 
baseline in mean trough SeSBP/SeDBP were 3.3/8.2 mm Hg, 20.1/16.4 mm Hg, and 
26.8/21.9 mm Hg with placebo, olmesartanmedoxomil/HCTZ 20/12.5mg, and 
olmesartanmedoxomil/HCTZ 40/25 mg, respectively. All treatments were well tolerated. 
Olmesartanmedoxomil/HCTZ combination therapy produced BP reductions of up to 
26.8/ 21.9 mm Hg and was well tolerated. [18] 
Giuseppe DeRosa et al, examined results from 12 months, randomized, clinical 
trial comparing an olmesartan/amlodipine single pill combination to olmesartan and 
amlodipine monotherapies on blood pressure and inflammation 26–
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33Olmesartan/amlodipine combination was more effective than amlodipine or 
olmesartan in reducing blood pressure. Olmesartan/amlodipine combination, but not 
amlodipine, decreased FPG after 12 months. Olmesartan/amlodipine combination better 
decreased FPI and HOMA index and increased M value compared to olmesartan and 
amlodipine monotherapies. Olmesartan/amlodipine significantly decreased chemerin 
and omentin compared to olmesartan and amlodipine. Other than to be more effective 
in reducing blood pressure, olmesartan/amlodipine single pill combination gave also a 
major increase in insulin sensitivity and a decrease of inflammatory markers compared 
to single monotherapies. [19] 
 S. Sayed et al, prepared Olmesartanmedoxomil surface solid dispersion-based  
oro dispersible tablets: formulation and in vitro characterization. This work aims to 
improve the dissolution of the poorly water soluble drug olmesartanmedoxomil by using 
the surface solid dispersion (SSD) technique. Insoluble carriers, namely Avicel PH 102, 
Aerosil 200, silicified microcrystalline cellulose, Lycatab, Starlac, sodium starch 
glycolate (SSG), and Kyron T-314, were used at three different drug: carrier ratios (1:1, 
1:5, and 1:9 w/w) to prepare SSDs by solvent evaporation method. SSD18 consisting of 
drug: SSG at 1:9 ratio and SSD20 consisting of drug: Kyron T-314 at 1:5 ratio showed 
the highest enhancement in the dissolution rate and efficiency compared to the plain 
drug and the physical mixture. The selected dispersion was formulated into 
orodispersible tablets (ODTs) by using four different disintegrants. F3 DC ODT 
(consisting of SSD20 and 5 % crospovidone) and F6 DC ODT (consisting of SSD18 and 
no disintegrant) exhibited low in vitro disintegration time and a high percentage of 
olmesartanmedoxomildissoluted within 10 min. [20] 
Steven G. Chrysant, et al, evaluated the Efficacy and safety of triple-
combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study 
participants with hypertension and diabetes: a subpopulation analysis of the TRINITY 
study. The prespecified changes in BP from baseline for the diabetes subgroup 
receiving triple-combination treatment were greater than the respective dual-
combination treatments (P _ .0013). Also, more participants with diabetes receiving 
triple combination treatment reached BP goal (<130/80 mm Hg) versus those receiving 
dual combination treatments. [21] 
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Henry A. Punziet et al, evaluated Efficacy and safety of 
olmesartan/amlodipine/HCTZ in hypertensives, not at goal with mono, dual or triple drug 
therapy: results of the champion study. They assessed the efficacy and safety of once 
daily olmesartanmedoxomil/ amlodipine besylate/HCTZ 40/10/25mg in patients with 
hypertension, not at goal with mono, dual or triple drug therapy in phase 4, single-
center, prospective, open-label, blinded-endpoint study. Adults with stage 1 or 2 
hypertension entered a 2-9 day screening period, followed by a 4-6week open-label 
treatment with OM/AM/HCTZ fixed dose combination. Safety and tolerability were 
assessed by recording treatment-emergent adverse events (TEAEs), monitoring vital 
signs and clinical laboratory parameters, and performing ECGs and physical 
examinations. Efficacy assessments included a change from baseline in trough sDBP 
and sSBP and percentage of patients who achieved BP goal. A total of 13 out of 40 
patients were _60 years of age (64% men and 36% women). TEAEs were experienced 
by 86% of patients and were mostly mild or moderate. The most common TEAEs were 
sinusitis (7.5%), swelling of both ankles (5.0%), tiredness (5.0%) swelling of both lower 
legs (2.5%) and worsening swelling of both feet (2.5%). There were no dizziness, 
syncope or serious AEs experienced and no deaths occurred. Mean baseline office 
SBP/DBP of patients aged _60 years was 140/86 mmHg and mean baseline ABPM 
SBP/DBP of patients aged _60 years was 134/ 75mmHg. After 24 hours of treatment 
with triple drug therapy mean office SBP/DBP was 129/79 mmHg (a SBP reduction of 
11.2mmHg and a DBP reduction of 7.8mmHg) and mean ABPM SBP/DBP of patients 
aged _60years was 129/73mmHg (an ambulatory SBP reduction of 5.1mmHg and an 
ambulatory DBP reduction of 2.3mmHg), after 1 week of treatment, mean office 
SBP/DBP was 122/77 mmHg (a SBP reduction of 18.2mmHg and a DBP reduction of 
9.4mmHg) and mean ABPM SBP/DBP of patients aged _60 years was 120/69mmHg 
(an ambulatory SBP reduction of 13.6mmHg and an ambulatory DBP reduction of 
6.0mmHg), after 2 weeks of treatment, mean office SBP/DBP was 121/ 76 mmHg (an 
SBP reduction of 18.7mmHg and a DBP reduction of10.2mmHg) and mean ABPM 
SBP/DBP of patients aged _60 years was 118/67mmHg (an ambulatory SBP reduction 
of 15.3mmHg and an ambulatory DBP reduction of 7.8mmHg), and after 4 weeks of 
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treatment, mean office SBP/DBP was 119/76 mmHg (an SBP reduction of 21.6mmHg 
and a DBP reduction of 10.7mmHg) and mean ABPM SBP/DBP of patients aged _60 
years was 116/67mmHg (an ambulatory SBP reduction of 17.2mmHg and an 
ambulatory DBP reduction of 8.2mmHg). In conclusion, triple drug therapy resulted in 
lower achieved SBP reduction (<140 mmHg) in patients over 60 and was well tolerated 
and without adverse effects on health or quality of life. As per JNC 8 recommendations, 
the triple drug treatment would not need to be adjusted in these patients. [22] 
Elizabeth O. Ofili, et al, studied the difference between the Moderate versus 
intensive treatment of hypertension using amlodipine/valsartan and with the addition of 
hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker 
monotherapy: results in racial/ethnic subgroups. Combination therapy may reduce 
racial/ethnic differences in response to antihypertensives. In this posthoc analysis, we 
evaluated treatment response by race/ethnicity among hypertensive adults enrolled in a 
12-week, double-blind study in which patients previously uncontrolled (mean sitting 
systolic blood pressure [MSSBP] _150 and <200 mm Hg) on angiotensin receptor 
blocker (ARB) monotherapy (other than valsartan) for 28 days or more (n ¼ 728) were 
randomized to amlodipine/valsartan 10/320 mg (intensive) or 5/160 mg (moderate). 
Treatment-na€ıve patients (in previous 28 days) or those who failed on a non-ARB first 
underwent a 28-day run-in period with olmesartan 20 mg or 40 mg, respectively. 
Hydrochlorothiazide (HCTZ) 12.5 mg was added to both arms at week 4; optional up-
titration to 25 mg at week 8 (if MSSBP >140 mm Hg). Intensive treatment provided 
greater BP lowering versus moderate treatment throughout the study, regardless. [23] 
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                                       AIM AND OBJECTIVE  
AIM: 
 To determine the direct compression of Amlodipine Besylate and Olmesartan 
Medoxomil using by SeDem. 
OBJECTIVES: 
 To developed and formulate the Amlodipine Besylate and Olmesartan 
Medoxomil  tablet in direct compression method  using by SeDem 
 The high cost of imported custom made directly compressible adjuvant. 
The primary reason for high cost of imported direct compression 
diluents is the use of spray drying.  
 Price control is One of the objectives of the present investigation was 
to develop an economical adjuvant so that the domestic manufacturers 
can meet the requirements of price control. The cost of starch is less 
as compared to that of lactose or MCC. Hence, starch based directly 
compressible adjutants were developed in the present investigation      
 Blends of treated starch also are explored for preparing quickly 
disintegrating tablets. A systematic evaluation of various blends of 
physically modified starch and microcrystalline cellulose or lactose for 
direct compression 
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PLAN OF WORK 
 The study was planned to carry out as follow, 
 Collection of literature review 
 Olmesartan medoxomil and Amlodipine besylate drug collection 
 Effect on solubility 
 Calibration curve of Olmesartan medoxomil and Amlodipine besylate 
 SeDem parameters 
 Bulk density  
 Tapped density  
 Inter-particle porosity  
 Carr index  
 Cohesion index  
 Hausner ratio  
 Angle of repose  
 Flow ability  
 Loss on drying  
 Hygroscopicity 
 Particle size 
 Homogeneity index 
 Direct compression of the tablets 
 Evaluation study of tablets 
 Weight variation test 
 Friability test 
 Hardness test 
 Dissolution test 
 SEM analysis of formulated tablets 
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DRUG PROFILE 
OLMESARTAN MEDOXOMIL: 
 
 
 
(5-methyl-2-oxo-1, 3-dioxol-4-yl) methyl-5-(2-hydroxypropan-2-yl)-2-propyl-3-
[[4-[2-(2H-tetrazol-5-yl) phenyl] phenyl] methyl] imidazole-4-carboxylate 
Mechanism of Action  
Angiotensin II is created from angiotensin I in a response catalyzed by 
angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the major presser 
cause of the renin-angiotensin system, with the effect that contains vasoconstriction, 
stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal 
reabsorption of sodium. Two subtypes make up the angiotensin II receptor: AT1 and 
AT2. Olmesartan Medoxomil blocks the vasoconstrictor effects of angiotensin II by 
selectively blocking the binding of angiotensin II to the AT1 receptor in vascular 
smooth muscle. Its act is, therefore, independent of the pathway for angiotensin II 
synthesis. 
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The Pharmacokinetic and Metabolic Profile of Olmesartan Medoxomil  
Orally administer Olmesartan Medoxomil was quickly absorbed from the 
gastrointestinal tract and changed through absorption to olmesartan, the 
pharmacologically active metabolite that was consequently excreted with no further 
metabolism. The medoxomil moiety was released as di acetyl that was rapidly 
cleared by further metabolism and excretion. Peak plasma concentrations of 
olmesartan occur 1-3 h following administration, after which concentration decreased 
quickly. The elimination half-life was 10-15 h. Olmesartan Medoxomil was not 
assessable in plasma excretion. The quantity of distribution was low, reliable with 
limited extra vascular tissue distribution. Bioavailability (Cmax and area under the 
curve) increased around in proportion to dose, later than single and multiple daily 
oral doses, more the therapeutic dose range (up to 40-80 mg daily), above which 
systemic availability of Olmesartan Medoxomil increased a lesser amount of the 
proportionally with the increase in dose. Steady-state plasma concentrations of 
Olmesartan Medoxomil were reached within the first little daily oral doses. On 
average, approximately 40% of systemically available olmesartan medoxomil was 
excreted by the kidneys, the remains life form excreted in feces, following secretion 
in bile. Renal clearance (0.5-0.7 l/h) was self-determining of dose, accounting for 
approximately 9-12% of an oral dose. The absolute bioavailability of olmesartan from 
Olmesartan medoxomil tablets was 28.6%. Olmesartan Medoxomil exhibits little or 
no required to blood cells. No clinically major steady-state pharmacokinetic 
interactions were observed following co-administration of Olmesartan Medoxomil 
with digoxin, warfarin, and aluminum magnesium hydroxide (antacid), supporting the 
low possible for clinically important pharmacokinetic interactions to occur between 
Olmesartan Medoxomil and co-administered drugs. [24] 
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AMLODIPINE BESYLATE 
 
 
 
3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy) methyl]-4-(2- chlorophenyl)-1,4-
dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. 
Mechanism of Action of Amlodipine Besylate: 
 Amlodipine Besylate is a dihydropyridine calcium competitor (calcium ion 
competitor or slow-channel blocker) that inhibits the Trans membrane entry of 
calcium ions into vascular soft muscle and cardiac muscle. 
Pharmacokinetics of Amlodipine Besylate: 
Amlodipine Besylate is a di-hydro pyridine calcium opponent drug with the 
typical pharmacokinetic character which appears to be attributable to a far above the 
ground extent of ionization. Following oral administration, bioavailability is 60 to 65% 
and plasma concentrations increase step by step to peak 6 to 8h later than 
administration. Amlodipine Besylate is expansively metabolized in the liver (but there 
is no significant pre-systemic or first-pass metabolism) and is little by little clear with 
a deadly elimination half-life of 40 to 50h. The volume of distribution is bulky (21 
L/kg) and around is a high degree of protein binding (98%). There is some evidence 
that age, strict hepatic impairment, and strict renal impairment power the 
pharmacokinetic profile most important to higher plasma concentration and longer 
half-lives. There is no proof of pharmacokinetic drug interactions. Amlodipine 
Besylate shows linear dose-related pharmacokinetic character and, at steady-state, 
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there are relatively small fluctuations in plasma concentration across a dosage 
interval. Thus, even though structurally connected to previous dihydropyridine 
derivatives, Amlodipine Besylate displays extensively different pharmacokinetic 
characteristics and is apposite for administration in a single daily dose. [25] 
EXCIPIENTS PROFILE 
ETHYL CELLULOSE: 
  Ethyl cellulose is a derived of cellulose in which a number of-of the hydroxyl 
group on the repeating glucose units are changed into ethyl ether groups. The 
number of ethyl groups can differ depending on the manufacturer. It is primarily 
used as a thin film matter. Ethyl cellulose is used as a food preservative as an 
emulsifier. 
Structure: 
 
Synonyms: 
Cellulose, ethyl ether; ethylated cellulose; ethyl cellulose 
Chemical Name: 
Ethyl cellulose, Aqua coat, Ethel, Surelease 
Molecular Formula: 
C20H38O11 
Molecular Weight: 
454.513 g/mol 
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Physical Properties: 
1. Colour: 
Pale needles since benzene [26], Free-flowing, white to brightness tan 
powder [27] vacant commercially as an obvious layer or sheet [28], White, 
granular, thermoplastic solid. [29] 
 
2. Melting point: 
240-255˚C [30] 
 
3. Solubility: 
Impenetrable in glycerin and propylene glycol (31) Freely soluble in a 
blend of Pungent hydrocarbons by alcohol [32] have an ethyl degree of 
alternative (DS) in the range of ~2.2 - 2.7. Water soluble at DS ~1.2.Above a 
DS of ca 2.5, soluble in a lot of polar solvents. [33]Soluble in mainly pure liquids 
 
4. Density 
1.07-1.18[34] 
 
5. stability: 
Extremely steady chemically, Cellulose ethers. [35]   
 
6. pH 
Aqueous suspensions are neutral to litmus. [36] 
 
Applications: 
 
1. description of Ethyl cellulose Films contain Natural Polysaccharides by 
Thermal examination and FTIR Spectroscopy 
2. estimate of ethyl cellulose as a matrix for controlled release drug delivery 
3. Physico-Mechanical examination of Free Ethyl cellulose Films 
Plasticized with Incremental mass Percents of DibutylSebacate 
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4. appliance of an Aqueous Ethyl cellulose distribution in Multiple-Unit Pellet 
system 
5. exercise of Xanthan Gum and Ethyl cellulose in Formulation of Metronidazole 
for Colon release 
6. appliance of Ethyl cellulose in Preparation of extensive Release Theophylline 
Inert Matrix Tablets by Wet Granulation 
7.  Starch or amylum is a polymeric carbohydrate consisting of a big number of 
glucose units connected by glycoside bond. This polysaccharide is formed by 
most green plants as an energy store up. It is the mainly common 
carbohydrate in human diets an  
STARCH 
It is restricted in great amounts in staple foods such as potatoes, wheat, 
maize (corn), rice, and cassava. Pure starch is a white, tasteless and odorless 
powder that is insoluble in freezing water or alcohol. It consists of two type of 
molecules: the linear and helical amylose and the branched amylopectin. Depending 
on the plant, starch generally contains 20 to 25% amylose and 75 to 80% 
amylopectin by weight.[37] Glycogen, the glucose store up of animals, is a more 
divided version of amylopectin. 
Molecularformula: 
        (C6H10O5) n 
Appearance:  
         White powder 
Density: 
         1.5g/cm3 
Melting point: 
         Decomposes 
Solubility: 
         Solubility in Water: insoluble (see starch gelatinization) 
Applications: 
1. Paper making is the major nonfood appliance for starches globally, consuming 
millions of metric tons annually 
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2. Ribbed penetrate adhesives are the next major application of non-food starches 
internationally. Starch glue is mainly based on unchanged native starches, plus 
some preservative such as borax and caustic soda. 
3. Clothes or laundry starch is a fluid to arranged by mixing a vegetable starch in 
water and is used in the launder of clothes 
4. Textile chemical from starch: bend sizing agents are used to reduce breaking of 
yarn in weaving. 
5. Starch is primarily used to size cotton base yarn. Modified starch is as well used 
as a textile print thickener. 
6. During oil assessment, starch is use to accurate the viscosity of drill fluid, which is 
use to lubricate the drill top and suspend the mill remains in petroleum origin. 
7. Starch is also used to create some packing peanuts and a number of drop ceiling 
tiles. 
8. In the printing manufacturing, food quality starch [38] is use in the produce of ant 
setoff spray powder used to separate printed sheets of paper to avoid wet ink 
organism set off. 
9 .For body powder, powdered corn starch is used as an alternative for talcum 
powder, and equally in previous health and beauty products. 
10. Starch is used to generate a range of bioplastics, artificial polymers that are 
biodegradable. An example is a polylactic acid base on glucose from starch. 
11. Glucose from starch can exist further fermented to biofuel corn ethanol using the 
so-called wet milling process. Today most bioethanol manufacture plants use the dry 
mill process to agitation corn or other feedstock straight to ethanol. [39] 
12. Hydrogen manufacture can use glucose from starch as the raw material, using 
enzymes. 
STEARIC ACID 
It a saturated fatty acid with an 18carbon sequence and has the IUPAC 
name octadecanoic acid. It is a waxy solid and its substance formula is 
C17H35CO2H. Its name comes from the Greek word "stear", which means tallow. 
The salts and esters of stearic acid are called stearates.  As its ester stearic acid is 
on own of the primarily universal saturated fatty acids found in nature follow 
palmitic acid.[40]  The triglyceride derived from three molecules of stearic acid is call 
stearin. 
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Structure: 
  
 
 
Chemical formula: 
C18H36O2 
Molar mass: 
 284.48 g·mol−1 
Appearance: 
White solid 
Odour: 
Pungent, oily 
Density: 
0.9408g/cm3 (20 °C) 
0.84 g/cm3 (70 °C) 
Melting point: 
 69.3 °C (156.7 °F; 342.4 K)  
Boiling point 
361 °C (682 °F; 634 K) 
Decomposes 
232 °C (450 °F; 505 K)at 15 mmHg[41] 
Solubility 
Soluble in alkyl acetates, alcohols, HCOOCH3, phenyls, CS2, CCl4[42] 
Application: 
1.In universal, the application of stearic acid develops its bifunctional nature 
with a polar top group that can be attached to metal cations and a no polar 
chain that confer solubility in organic solvents.  
2. The grouping leads to uses as a surfactant and softening agent. Stearic 
acid undergo the typical reaction of saturated carboxylic acids, a noteworthy 
One being a reduction to stearyl alcohol, and etherification with a range of alcohols.  
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3. This is used in a large variety of manufacture, from simple to difficult 
electronic devices. 
Magnesium stearate: 
Magnesium stearate is the substance with the formula Mg(C18H35O2)2. It is 
soap, consisting of salt contain two equivalent of stearate (the anion of stearic acid) 
and one magnesium cation (Mg2+). Magnesium stearate is a white, water-insoluble 
powder. Its applications exploit its softness, insolubility in many solvents, and low 
toxicity. It is used as a release mediator and as a component or lubricant in the 
manufacture of pharmaceuticals and cosmetics. [50] 
IUPAC name: 
Magnesium octadecanoic 
Chemical formula: 
 Mg (C18H35O2)2 
Molar mass: 
 591.27 g/mol 
 
Physical Properties: 
Appearance: 
 Light white powder 
Odour: 
 Slight 
Density: 
 1.026g/cm3 
Melting point: 
 88.5 °C (191.3 °F; 361.6 K) 
Solubility in water: 
 0.003 g/100 ml (15 °C) 
0.004 g/100 ml (25 °C) 
0.008 g/100 ml(50 °C) 
Solubility: 
Negligible in ether and alcohol 
Slightly soluble in benzene 
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Applications: 
1. Magnesium stearate is frequently used as an anti-adherent [51] in the generate 
of medical tablets, capsules, and powders.[43]  
2. Magnesium stearate can moreover be used effectively in dry coating 
processes[44,45,46] 
3. Magnesium stearate is also used to attach sugar in hard candies like mints 
and is a general element in baby formulas. 
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MATERIALS AND MANUFACTURER 
 
 
 
 
 
S.NO 
 
 
NAME OF THE MATERIAL 
 
SOURCE/SUPPLIER/MANUFACTURER 
 
                           
1. SODIUM HYDROXIDE MOLYCHEM 
2. POTASSIUM DIHYDROGEN 
ORTHO PHOSPHATE 
REACHEM LABORATORY 
3. AMLODIPINE BESYLATE GIFT SAMPLE OF CAREWELL, 
CHENNAI. 
4. OLMESARTAN MEDOXAMIL GIFT SAMPLE OF G.K.M. 
LABORATORY, PUTHUCHERRI. 
5. STARCH FISCHER LABORATORY REAGENT 
6. ETHYL CELLULOSE ROLEX LABORATORY 
7. STEARIC ACID HIMEDIA LABORATORIES.Pvt.Ltd 
8. MAGNESIUM STEARATE MODERN SCIENTIFIC.CO 
9. ETHYL CELLULOSE LR SDFINE – CHEM. Ltd 
  
 
LIST OF EQUIPMENTS / 
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LIST OF EQUIPMENTS/ INSTRUMENTS 
 
 
S.NO 
 
 
EQUIPMENTS/ INSTRUMENTS 
 
MANUFACTURE/SOURCE 
 
1. 
 
 
ELECTRONIC BALANCE 
 
SHIMADZU ELB 300 
 
2. 
 
 
HOT AIR OVEN 
 
ELCON 
 
3. 
 
 
MAGNETIC STIRRER 
 
REMI 
 
4. 
 
 
DISSOLUTION TEST APPARATUS 
 
LABINDIA DISSOO 2000 
 
5. 
 
 
UV SPECTRO PHOTO METER 
 
SHIMADZU UV -1700 
 
6. 
 
 
PH 
 
AGRONIL 511 
 
7. 
 
 
MICROSCOPE 
 
A.K.C.P 
 
8. 
 
 
TABLET COMPRESSION MACHINE 
 
RIMEK MINI PRESS-1 
 
9. 
 
 
DISINTEGRATION TEST 
APPARATUS 
 
ROLEX 
10.  
SEM ANALYSER 
 
ZEISS-5200 SEM 
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   EXPERIMENTAL WORK 
DEVELOPMENT OF CALIBRATION CURVE: 
Preparation of Buffer Solution (pH-7.4) [47]  
750ml of potassium dihydrogen phosphate solution (27.218gm of potassium 
dihyrogen ortho phosphate in 1000ml) and 586.5ml of NaoH (8gm in 1000ml) were 
mixed properly and the volume was made up to 1000ml with distilled water 
Preparation of Standard Solution of Amlodipine Besylate Sample: [48] 
 A solution of 10mg Amlodipine Besylate was prepared by dissolving in 5ml 
ethanol and 95ml phosphate buffer pH 7.4, from which 0.5ml was withdrawn in 
separate volumetric flask and dilute to make 10ml with phosphate buffer to produce 
5µg/ml concentration and absorbance at 365nm. 
Preparation of Working Solution: 
 From standard solution 0.5, 1, 1.5, 2 and 2.5 was withdrawn in five 10ml 
volumetric flask and dilute to make 10ml with phosphate buffer pH 7.4, to produce 
concentration 5, 10, 15, 20 and 25µg/ml respectively.  The solution were analysed by 
UV-Spectrophotometer at 365nm and result were recorded.  The calibration graph 
was plotted as concentration on x-axis vs. absorbance on y-axis. 
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Table No: 7.1 Standard Curve of Amlodipine Besylate: 
S.No. Concentration 
(µg/ml) 
Absorbance Slope Average Slope 
1. 5 0.051 0.0102  
 
0.011752 
2. 10 0.116 0.0116 
3. 15 0.179 0.0119 
4. 20 0.242 0.0121 
5. 25 0.324 0.01296 
 
 
 
Figure: 7.1 Standard Curve of Amlodipine Besylate 
Preparation of Standard Solution of Olmesartan Medoxomil Sample: [48] 
            A solution of 10mg Olmesartan Medoxomil was prepared by dissolving in 5ml 
ethanol and 95ml phosphate buffer pH 7.4, from which 0.5ml was withdrawn in 
separate volumetric flask and dilute to make 10ml with phosphate buffer to produce 
5µg/ml concentration and absorbance at 257nm 
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Preparation of Working Solution: 
 From standard solution 0.5, 1, 1.5, 2 and 2.5 was withdrawn in five 10ml 
volumetric flasks and dilute to make 10ml with phosphate buffer pH 7.4, to produce 
concentration 5, 10, 15, 20 and 25µg/ml respectively.  The solution was analyzed by 
UV-Spectrophotometer at 257nm and result were recorded.  The calibration graph 
was plotted as concentration on x-axis vs. absorbance on y-axis 
Table No: 7.2Standard Curve of Olmesartan Medoxomil: 
S.No. Concentration 
(µg/ml) 
Absorbance Slope Average Slope 
1. 5 0.169 0.0338  
 
0.035914 
2. 10 0.387 0.0387 
3. 15 0.481 0.0320 
4. 20 0.771 0.03855 
5. 25 0.913 0.03652 
 
 
 
Figure: 7.2 Standard Curve Of Olmesartan Medoxomil 
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Effect on Amlodipine Besylate Solubility: 
 A known amount of sample of Amlodipine Besylate added in 50ml of ethanol 
and kept for 3 hours occasionally stirring.  After 3 hours contents were filtered 
through the Whatman filter paper and appropriate dilutions were made with 0.2M 
phosphates buffer and the absorbance of the resultant solution was measured at 
365nm and extrapolated on the standard graph to determine the concentration. 
Effect on Olmesartan Medoxomil Solubility: 
 A known amount of sample of Olmesartan Medoxomil added in 50ml of 
ethanol and kept for 3 hours occasionally stirring.  After 3 hours contents were 
filtered through the Whatman filter paper and appropriate dilutions were made with 
0.2M phosphate buffer and the absorbance of the resultant solution was measured 
at 257nm and extrapolated on the standard graph to determine the concentration. 
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SEDEM PARAMETERS: 
Bulk Density (Da): 49 
 
Bulk density is defined as the mass of a powder divided by the bulk volume. 
The bulk density of a powder depends primarily on particle size distribution, particle 
shape and the trend of the particles to remain to one another. 
Method: 
Both loose bulk density (LBD) and tapped bulk density (TBD) were 
determined. A measure of correctly weigh powder (bulk) since each formula, 
Before shaken to crack any agglomerates formed was introduced into a 100ml 
measuring cylinder. Behind the primary volume was observed, the cylinder be 
allowed to reduce under its own weight on to a hard surface from the height of 2.5cm 
at 2 sec interval. The tapping is constant until no additional change in volume was 
noted.  
 
                                                    Mass of the powder 
LBD (Loose Bulk Density) = --------------------------------- 
                                                         Bulk volume 
Tapped Density (Dc):50 
The measuring cylinder contain a known mass of blend was tapped for an 
unchanging time. The smallest amount volume (Vt) full in the cylinder and the weight 
(M) Of the blend was measured. The tapped density (λt) be calculate using the track 
formula  
                                                            M 
                                                     t = ------ 
                                                             V 
Where, 
 M = Mass of the powder 
  V = Tapped volume 
 t = Tapped density 
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Carr Index (Ic): 
This is calculated from Da and Dc as 
        (Dc – Da) 
Ic = --------------- x 100 
                                    Dc 
Cohesion Index (Icd): 
 The maximum value is determined empirically from compression test on many 
powdered substances, based on the largely hardness obtained with no producing 
capped or broken tablets. This stiffness is then establish as the maximum limit. The 
minimum value is “0”. These values imply that no tablets are obtained when the 
powders are compressed. The denote stiffness (N) of the tablets is calculated. First, 
the untreated powder is tested, however if it cannot be compressed, 3.5% of the 
following combination is added to the mix: talc¼2.36%, Aerosil (Evonik, Germany) 
200¼0.14% and magnesium stearate¼1.00%. 
Hausner’s ratio (IH): [51] 
Hausner’s ratio is an indirect index of ease of powder flow. It is calculated by 
the following formula  
 
                                                    Dc              
                                   IH     = ----------- 
                                                    Da 
 
Angle of Repose (θ): [52] 
The frictional forces during a loose powder or granules can be measured by 
the angle of repose. This is the most direction possible between the plane of a pile of 
powder or granules and the horizontal plane. 
 
                                tanθ = h/r θ = tan-1 (h/r) 
 
Where θ is the angle of repose, h is the height, r is the radius. 
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Table No: 7.2 a Angle Of Repose Flow Property 
 
S.No Angle Of Repose Flow Property 
 
1. 
 
Less than 25˚ 
 
Excellent flow 
 
2. 
 
25˚ to 30˚ 
 
Good 
 
3. 
 
30˚ to 40˚ 
 
Possible flow 
 
4. 
 
greater than 40˚ 
 
Very poor 
 
Funnel Method: 
A funnel was filled to the brim and the test sample was allowed to flow 
smoothly through the orifice under gravity. From the cone formed on a graph, the 
sheet was taken to measure the area of the pile, there by evaluating the flow ability 
of the granules. The height of the pile was also measured. 
Open End Cylinder Method: 
10g of powder was weighed accurately with an electronic weighing balance. 
The powder was then put into a cylinder that was stopped by rubber closure at one 
end. The cylinder was pulled and the mixtures were allowed to flow down to form a 
heap on the stopper. The height, diameter and angle height of the powder heap were 
recorded. The angle of repose of the powder mass was calculated. 
Flowability (t″): [53] 
It is expressed in seconds and tenths of a second per 10 grams of sample, 
with a mean value of two measurements 
1) Open end cylinder method 
2) Funnel method 
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LOSS ON DRYING (%HR) 
PROCEDURE 
Dry a weighing bottle for about 30 minutes under the prescribed conditions, 
allow cooling it in desiccators if heated, and weigh it accurately. If the powder is large 
crystals or lumps, promptly crush it into particles not larger than about 2 mm in 
diameter and, unless otherwise specified, place 1 to 2 g into the weighing bottle, 
spread the powder so that the layer is not thicker than 5 mm, and weigh it accurately. 
Place the bottle in the drying oven, remove the stopper (placing it nearby), dry under 
the specified conditions, stopper again, take the bottle out of the oven, and weigh it 
again. If heated, unless otherwise specified, allow to cool it in desiccators, and weigh 
it accurately. If the powder melts at a temperature lower than the specified drying 
temperature, dry it at a temperature 105 °C ± 2 °C lower than the melting 
temperature for 1 to 2 hours, and dry it under the specified conditions. 
 
Loss on drying = Initial weight of the drug – Final weight of the drug X 100 
 
HYGROSCOPICITY (%H): 
 Determination of the percentage increase in sample weight after being kept in 
a humidifier at a relative humidity of 76% (±2%) and a temperature of 22°C± 2°C for 
24 h. 
 
Hygroscopicity = (Final weight of the drug – initial weight of the drug) X 100 
 
PARTICLE SIZE (% PF) OF DRUG BY EYE PIECE MICROMETER: 
PRINCIPLE: 
The particle size can define as the diameter of the sphere, equivalent to the 
particle in weight, volume, surface area, and projected area. When the particle size 
is analyzed by microscope, it is referred as the projected diameter of the sphere, 
which is the same projected area of the particle size with the effective procedure. It is 
the only method in which direct measurement of the particles is made. The particle 
size distribution is represented in the graphical form as “Histogram” – Frequently 
distribution curve or cumulative distribution curve. Some samples may be similar 
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average size but differ in distribution. Such differences are flatted in a graphical form 
as “Histogram”. It gives the number of the particle diameter but not actual size. The 
cumulative distribution curve gives the % of any given sample. 
PROCEDURE: 
Calibration of the Eyepiece micrometer is done with the division of Eyepiece 
micrometer scale co-inside with the division of the stage micrometer. 
CALIBRATION OF EYEPIECE MICROMETER:- 
 1 Division of stage micrometer = 0.01mm = 10 micron 
           
                                                          No. of division of stage micrometer 
1 Division of Eye-piece micrometer = ------------------------------------------ x 10 
                   No. of division of Eyepiece  
          Micrometer 
 
A small amount of the sample is diluted with the solvent (water, liquid paraffin 
(or) Glycerine) few drops of the above solution is transferred on a glass side and 
focused under a microscope by using an Eyepiece micrometer, the diameter of the 
100 particles determined by the number of the division of Eye-piece micrometer. This 
is then converted to microns the particles are arranged on the basis of the size 
range; the number of the particles in each size range are then counted and 
calculated. Then the percentage in each interval and percentage undersize are 
calculated. The histogram and cumulative curves are flatter. 
DETERMINATION OF SAMPLE DRUG PARTICLE SIZE BY SIEVING METHOD 
PRINCIPLE: 
Particle size can affect the flow property method of sieving may be employed 
for screening material fine as under 100. The Sample powder is shaken for a 
definite period of time and material passes through the one sieve retained on the 
next fine sieve, collect and weigh the sample. The sieves are arranged in a nest with 
the coarse at the top and fine at the bottom. Carefully weigh the sample of the 
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powder, placed on the top sieve and after the sieves are shaken for free determine 
period of time, the sample powder retain on each sieve is weighed. An arithmetic 
mean of the sample is determined. 
PROCEDURE: 
10gm of the sample is weighed and placed on the top sieve of the arranged 
sieves, mechanically shaken for 20 minutes. The sieves are then removed and the 
drug was retained on each sieve are weighed and the results are calculated. The 
percentage weight of the powder retain is calculated. Weight size is calculated from 
the percentage weight of the retained. Arithmetic mean is calculated. The 
percentage undersize is calculated by adding the value of the percentage of the 
weight of powder. The percentage oversize is calculated by the values, the 
percentage of the weight of drug retained. Cumulative percentage curves are plotted. 
 
Weigh size = Arithmetic mean size of opening x percentage of 
            powder obtained 
               
                            Weigh size               
Arithmetic mean =--------------------  
             100                        
Percentage under size (adding up to weight size) Percentage oversize (From 
the 100 subtract the values) 
HOMOGENEITY INDEX (Iθ): 
To determine particle size by means of the sieve test, the grain size of a 100g 
sample is measured by subjecting a sieve stack to vibration for 10 min at speed 10 
(CISA vibrator). The sieve sizes used are 0.355 mm, 0.212 mm, 0.100 mm and 0.05 
mm. The percentage of product retained on each sieve is calculated and the amount 
that passes through the 0.05mm sieve is measured. The percentage of fine particles 
(<50 μm) (%Pf) was calculated as described above. Note that if this percentage is 
higher than that calculated in the complete sieve test, it is because some of the 
particles become Expert Systems for Human, Materials and Automation 20 adhered 
to the product retained in the sieves during the grain-size test, and the percentage of 
<50 μm particles found may be lower than the true figure. The following equation is 
then applied to the data obtained. 
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                                                      Fm 
Iθ = ----------------------------------------------------------------------------------------------------------- 
         100+(dm-dm-1)Fm-1+(dm+1-dm)Fm+1+(dm-dm-2)Fm-2+(dm+2-dm)Fm+2 
            +(dm-dm-n)Fm-n+(dm+n-dm)Fm+n 
 
 
Where: 
•  Iθ, Relative homogeneity index. Particle size homogeneity in the range of the 
fractions studied; 
•  Fm, percentage of particles in the majority range; 
•  Fm−1, percentage of particles in the range immediately below the majority 
range; 
•  Fm+1, percentage of particles in the range immediately above the majority 
range; 
•  n, order number of the fraction studied under a series, with respect to the 
major fraction; 
     •  dm, mean diameter of the particles in the major fraction; 
•  dm−1, mean diameter of the particles in the fraction of the range immediately 
below the majority range; 
•  dm+1, mean diameter of the particles in the fraction of the range immediately 
above the majority range. 
 
Tablet Compression: 
Direct compression is the simplest and most economical method to 
manufacture tablets with active pharmaceutical ingredients(API) being blended with 
other directly compressible ingredients. 
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Table No: 7.3 Amlodipine Besylate Formulation Formula: 
S.No Ingredients Official Formula 
For 1 Tablets(mg) 
Working Formula 
For 50 Tablets(g) 
1. Amlodipine Besylate 10mg 0.5mg 
2. Starch 69.62mg 3.481g 
3. Ethyl cellulose 69.62mg 3.481g 
4. Magnesium stearate 0.74mg 0.037g 
5. Total 150mg 7.499g 
 
 
Table No:7.4 Olmesartan Medoxomil Formulation Formula: 
S.No Ingredients Official Formula 
For 1 Tablets(mg) 
Working Formula 
For 50 Tablets(g) 
1. Olmesartan Medoxomil 10mg 0.5g 
2. Starch 69.62mg 3.481g 
3. Ethyl cellulose 69.62mg 3.481g 
4. Stearic acid 0.74mg 0.037g 
5. Total 150mg 7.499g 
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EVALUATION OF TABLETS 
 The formulated tablets were evaluated for the following parameters. 
A. Weight Variation: 
20 tablets were weighed both collectively and individually.  From the collective 
weight, the average weight was calculated.  Each tablet weight was then compared 
with average weight to ascertain whether they are within permissible limits or not. 
 
    Average weight – Individual weight  
% Weight Variation  =      X 100 
                                                          Average weight 
 
B. Hardness: 
 The hardness of tablet was determined using the Monsanto hardness tester.  
The lower plunger was placed in contact with the tablet and a zero reading was 
taken.  The plunger was then forced against a spring by turning a threaded bolt until 
the tablet fractured.  As the spring was compressed a pointer rides along a gauge in 
the barrel to indicate the force. 
 
C. Friability: 
 The Roche friability test apparatus was used to determine the friability of the 
tablets.  20 pre-weighed tablets were placed in the apparatus, which was subjected 
to 100 revolutions.  Then the tablets were reweighed.  The percentage friability was 
calculated using the formula. 
       Initial weight – Final weight  
% Friability =              X 100 
                                  Initial weight 
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D. In-Vitro dissolution studies: 
 Dissolution rate was studied using USP II paddle dissolution apparatus, in 
900ml of phosphate buffer at 37±0.5˚ at 100 rpm.  Aliquot of dissolution medium was 
withdrawn at regular time intervals and the same volume of pre-warmed (37±0.5˚) 
fresh dissolution medium was replaced.  The samples were filtered and drug content 
of Olmesartan Medoxomil and Amlodipine Besylate in each sample was analyzed 
after suitable dilution by Shimadzu UV-Spectrophotometer at 257 nm & 365 nm 
individually. 
E.SEM [Scanning Electron Microscope] 
SEM analysis used to measure the particle size and shape. The 
morphological appearance of the electrospun fiber and that fiber were investigated 
by a ZEISS-5200 scanning electron microscope (SEM), operating at an acceleration 
voltage of 20 KV. For each sample, the average diameter of the individual fibers was 
measured from multiple SEM images at the magnification of 2.0 KX by semaphore 
4.0 software. The result of each sample was reported as an average value from at 
least three measurements. A Lloyd LRX universal tester was used to determine the 
mechanical integrity of some of the as-spun fibers. The gauge length and the 
crosshead speed were 10 µm per minute, respectively. [54, 55] 
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RESULT AND DISCUSSION 
AMLODIPINE BESYLATE: 
Bulk Density (Da): 
                                                         Mass of the powder 
LBD (Loose Bulk Density) = ---------------------------------  
                                                              Bulk volume 
 
      10 
= --------- 
                                                             32 
 
                                                      = 0.31 gm/ml 
 
The acceptable range of Bulk density is 0 - 1g/ml in my study Amlodipine 
Besylate bulk density range is 0.31 gm/ml so this drug is allow suitable for direct 
compression by SeDeM 
 
Tapped density (Dc): 
 
                          Mass of the powder 
    Tapped density = ------------------------------ 
                                      Tapped volume    
                                                    
                                                         10 
                                                   =  --------- 
                                                         22 
                                                  = 0.45 gm/ml 
 
The acceptable range of Tapped density is 0 – 1g/ml in my study Amlodipine 
Besylate Tapped density range is 0.45gm/ml so this drug is make suitable for direct 
compression by SeDeM 
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Average bulk density: 
                                                               Da + Dc 
Average bulk density =   ---------------- 
                                                                     2 
 
                                                             0.31 + 0.45 
                                                        =   ------------------ 
                                                                   2  
 
                                                        = 0.38 gm/ml 
Inter Particle Porosity (Ie): 
  
       Da 
 Inter particle Porosity =         1 -      ---------------------- 
        Dc 
 
       = 1 – (0.31/0.45) 
                      Porosity = 1- 0.688 
                 = 0.311  
The acceptable range of Inter Particle Porosity is 0 – 1.2 Amlodipine Besylate 
Inter Particle Porosity range is 0.311 so this drug is suitable for direct compression 
by SeDeM 
Carr,s Index (Ic): 
                           (Dc – Da) 
Ic         = --------------- x 100 
                      Dc 
 
                           0.45 – 0.31 
                       = ----------------- x 100 
                                 0.45 
 
                       = 0.311 x 100 
 
                       = 31.11% 
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The acceptable range of Carr Index is 0 – 50 % in my study Amlodipine 
Besylate Carr,s Index range is 31.11%so this drug is agreed to suitable for direct 
compression by SeDeM. 
Cohesion Index (Icd): 
The acceptable range of Cohesion Index is 0 – 200N but our Amlodipine 
Besylate Cohesion Index is 1.22N so this drug is making suitable for direct 
compression by SeDeM. 
Hausner’s ratio (IH): 
                                                    Dc              
                                   IH     = ----------- 
                                                    Da     
 
                                                     0.45 
                                             = -------------    
                                                     0.31           
 
                                             = 1.451 
 
When it is the tapped density and d is bulk density. Lower H(<1.25) indicates 
better flow properties than higher ones(>1.25). The acceptable range of Hausner’s 
ratio is 1 – 3 Amlodipine Besylate Hausner’s ratio is 1.451 so this drug is suitable for 
direct compression by SeDeM. 
Angle of Repose (θ): 
tanθ = h/r θ = tan-1 (h/r) 
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Table No: 8.1Angle of Repose of Amlodipine Besylate by Funnel Method 
 
Name 
of 
the Drug 
Powder 
 
Height 
of the 
Pile 
(h) cm 
 
Diameter 
of the 
Pile (d) 
cm 
 
Radius of 
the Pile (r) 
cm 
 
h/r 
 
Ԛ= tan-1 
(h/r) 
 
Average 
 
Amlodipine 
besylate 
 
2.4 
 
2.5 
 
2.2 
 
7.3 
 
7.3 
 
7 
 
 
 
3.7 
 
3.7 
 
3.5 
 
0.65 
 
0.68 
 
0.63 
 
33˚.02’ 
 
34˚.21’ 
 
32˚.21’ 
 
 
 
33˚.02’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULT AND DISCUSSION 
 
Department Of Pharmaceutics 
Arulmigu Kalasalingam College Of Pharmacy  Page 50 
 
ANGLE OF REPOSE OF AMLODIPINE BESYLATE DRUG BY FUNNEL METHOD 
GRAPH: 
 
1. h = 2.4 cm 
d = 7.3 cm 
r = 3.7 cm 
 
 
 
2. h = 2.5 cm 
d = 7.3 cm 
r = 3.7 cm 
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3. h = 2.2 cm 
d = 7 cm 
r = 3.5 cm 
 
               The Amlodipine Besylate powder is a possible flow. The acceptable range 
of Angle of Repose is 0 – 50 ˚ in my study Amlodipine Besylate Angle of Repose by 
funnel method is 33˚.02’ so this drug is suitable for direct compression by SeDeM. 
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Table No: 8.1 Angle of Repose of Amlodipine Besylate by Open End Cylinder 
Method 
 
 
Name 
of 
the Drug 
Powder 
 
Height 
of The 
Pile 
(h) cm 
 
Diameter 
of The 
Pile (d) 
cm 
 
Radius of 
the Pile (r) 
cm 
 
h/r 
 
Ԛ = tan-1 
(h/r) 
 
Average 
 
Amlodipine 
Besylate 
 
2 
 
2.1 
 
2.1 
 
6.1 
 
6 
 
5.9 
 
 
 
3.1 
 
3 
 
3 
 
0.64 
 
0.7 
 
0.7 
 
32˚61’ 
 
34˚99’ 
 
34˚99’ 
 
 
 
34˚99’ 
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ANGLE OF REPOSE OF AMLODIPINE BESYLATE  DRUG BY OPEN END 
CYLINDER METHOD GRAPH: 
 
1. h = 2.5 cm 
d = 7.3 cm 
r = 3.7 cm 
 
2. h = 2.2 cm 
d = 7.2 cm 
r = 3.6 cm 
 
 
 
 
 
 
 
 
RESULT AND DISCUSSION 
 
Department Of Pharmaceutics 
Arulmigu Kalasalingam College Of Pharmacy  Page 54 
 
3. h = 2.2 cm 
d = 7.1 cm 
r = 3 cm 
 
 
 
 
 The AmlodipineBesylate powder is a possible flow. The acceptable range of 
Angle of Repose is 0 – 50 ˚ in my study Amlodipine Besylate Angle of Repose by 
open end cylinder method is 34˚99’ so this drug is suitable for direct compression by 
SeDeM. 
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Flowability (t″): 
Open End Cylinder Method 
 
Sample = Amlodipine Besylate 
 
Table No: 8.2 Flowability of Amlodipine besylate by open end cylinder method 
 
S.NO PASSING TIME 
(Sec) 
1. 3 sec 
2. 4 sec 
3. 2 sec 
 
                                          Average mean= (3+4+2)/3 
= 3sec 
          The acceptable range of Flow ability is 0 – 20sec in my study  Amlodipine 
Besylate Flow ability is 3 sec so this drug is agreed to suitable for direct compression 
by SeDeM. 
LOSS ON DRYING (%HR): 
 
 Loss on drying = Initial weight of the drug – Final weight of the drug X 100 
 
                          = 10 – 9.78X 100 
 
                          = 0.22 X 100 
 
                          = 22% 
 
The acceptable range of loss on drying is 0 – 10(%)in my study  Amlodipine 
Besylate loss on drying is 22%so this drug is may be suitable for direct compression 
by SeDeM. 
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HYGROSCOPICITY (%H): 
Hygroscopicity = (Final weight of the drug – initial weight of the drug) X 100 
                        = 10.19 -10 
                        = 0.19 X 100 
                        = 19% 
 
             The acceptable range of hygroscopicity is 0 – 20% in my study Amlodipine 
Besylate hygroscopicity is 19% so this drug is possible to suitable for direct 
compression by SeDeM. 
 
PARTICLE SIZE (% Pf) OF AMLODIPINE BESYLATE DRUG   EYE                               
PIECE MICROMETER: 
CALIBRATION OF EYEPIECE MICROMETER:- 
 1 Division of stage micrometer = 0.01mm = 10 micron 
             No. of division of stage micrometer 
1 Division of Eye-piece micrometer = --------------------------------------------------- x 10 
                   No. of division of Eye-piece  
       Micrometer 
 
One division of eye piece micrometer = 12.5 µm 
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Table No: 8.3 PARTICLE SIZE (% Pf) OF AMLODIPINE BESYLATE DRUG BY 
EYE PIECE MICROMETER: 
S.NO EYEPIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
S.NO EYEPIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
1. 5 62.5 41. 6 75 
2. 3 37.5 42. 2 25 
3. 4 50 43. 3 37.5 
4. 6 75 44. 3 37.5 
5. 2 25 45. 2 25 
6. 1 12.5 46. 2 25 
7. 4 50 47. 1 12.5 
8. 2 25 48. 6 75 
9. 3 37.5 49. 6 62.5 
10. 7 87.5 50. 5 62.5 
11. 6 75 51. 4 50 
12. 2 25 52. 2 25 
13. 3 37.5 53. 3 37.5 
14. 1 12.5 54. 4 50 
15. 2 25 55. 5 62.5 
16. 3 37.5 56. 6 75 
17. 3 37.5 57. 1 12.5 
18. 4 50 58. 2 25 
19. 6 75 59. 3 37.5 
20. 1 12.5 60. 5 62.5 
21. 5 62.5 61. 4 50 
22. 4 50 62. 4 50 
23. 3 37.5 63. 4 50 
24. 3 37.5 64. 6 75 
25. 2 23 65. 7 87.5 
26. 4 50 66. 4 50 
27. 5 62.5 67. 3 37.5 
28. 3 37.5 68. 2 25 
29. 2 25 69. 1 12.5 
30. 3 37.5 70. 6 75 
31. 4 50 71. 5 12.5 
32. 5 62.5 72. 4 50 
33. 3 37.5 73. 4 50 
34. 3 37.5 74. 3 37.5 
35. 1 12.5 75. 2 25 
36. 3 37.5 76. 1 12.5 
37. 2 25 77. 2 25 
38. 3 32.5 78. 2 25 
39. 4 50 79. 3 37.5 
40. 3 37.5 80. 4 50 
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S.NO EYE PIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
S.NO EYE PIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
81. 5 62.5 91. 3 37.5 
82. 6 75 92. 3 37.5 
83. 7 87.5 93. 4 50 
84. 7 87.5 94. 5 62.5 
85. 3 37.5 95. 2 25 
86. 3 37.5 96. 6 75 
87. 3 37.5 97. 7 87.5 
88. 2 25 98. 2 25 
89. 4 50 99. 3 37.5 
90. 5 62.5 100. 4 50 
 
Table No: 8.4 CALIBRATION OF AMLODIPINE BESYLATE 
S.NO AVERAGE SIZE MIDPOINT NO.OF PARTICLES PRESENT 
1. 0-20 10 8 
2. 20-40 30 47 
3. 40-60 50 19 
4. 60-80 70 21 
5. 80-100 90 5 
 
 
Figure: 8.4 PARTICLE  SIZE  DISTRIBUTION OF AMLODIPINE BESYLATE 
The Amlodipine Besylate Average  particle size is  44.5µ  then it’s  
particle mean diameter  level is  44.5µ, and it,s total number of  size range  is  
0-100 µ  and  Amlodipine Besylate Size range of which maximum particle 
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exist  is 20-40 µm and finally Mode diameter is 25 µ,37.5 µThe acceptable 
range of particle size is 50µ in my study Amlodipine Besylate particle size by 
eye piece micrometer is 44.5µ so this drug is suitable for direct compression 
by SeDeM. 
Table No: 8.5DETERMINATION OF AMLODIPINE BESYLATE DRUG PARTICLE 
SIZE BY SIEVING METHOD: 
 
S.NO 
 
Sieve no 
 
Sieve  
opening 
(µ) 
 
Mean size 
opening 
(µ) 
 
Weight of the 
Drug retain 
(gms) 
 
Percentage 
weight of 
the Drug 
 
Weight 
size 
1. 80 177 177 0.67 x 10 = 6.7 6.7% 1185.9 
2. 80/100 177/149 163 0.80 x 10 = 8 8% 1304 
3. 100/120 149/125 211.5 1.05 x 10 = 
10.5 
10.5% 2220.75 
4. 120 125 125 6.02 x 10 = 
60.2 
60.2% 7525 
5. Total Weight of the drug Percentage & Weigh Size 85.4% 12235.65 
 
  
 
Weigh size = Arithmetic mean size of opening x percentage of weight 
       of the  powder obtained 
 
       Weigh size              12235.65 
Arithmetic mean =-------------------- = ---------------- = 122.37µ 
             100                       100 
 
Percentage under size (adding up to weight size) 
Percentage oversize (From the 100 subtract the values) 
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Table No: 8.6AMLODIPINE BESYLATE DRUG PARTICLE SIZE BY SIEVING 
METHOD: 
S.NO 
Weight of Drug 
Retained (gm) 
Particle Size 
Opening () 
Weight of 
Under Size 
Weight of 
Oversize 
 
1. 
2. 
3. 
4. 
 
 
6.7 
8 
10.5 
60.2 
 
177 
163 
211.5 
125 
 
6.7 
14.7 
25.2 
85.4 
 
93.3 
85.3 
74.8 
14.6 
 
 The arithmetic mean of is Amlodipine Besylate122.37µ 
 
HOMOGENEITY INDEX (Iθ): 
                                                       Fm 
Iθ = ----------------------------------------------------------------------------------------------------------- 
         100+(dm-dm-1)Fm-1+(dm+1-dm)Fm+1+(dm-dm-2)Fm-2+(dm+2-dm)Fm+2 
            +(dm-dm-n)Fm-n+(dm+n-dm)Fm+n 
 
22.21 
                    =  ------------------------ 
                              10287.001 
 
                  = 1.079%     
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Table No: 8.7 HOMOGENEITY INDEX OF AMLODIPINE BESYLATE 
Sieve (mm) Corresponding 
Average of 
the diameter 
of the 
fraction 
Corresponding 
diameter 
(dm……dm± n) 
Difference dm 
with the 
major 
component 
0.177 – 0.250 Fm + 2 11.86 dm + 2 10.35 
0.149 – 0.177 Fm + 1 13.04 dm + 1 9.17 
0.125 – 0.149 Fm 22.21 dm 0 
0.063 – 0.125 Fm – 1 75.25 dm - 1 53.04 
<0.063 Fm – 2 0 dm – 2 22.21 
 
Amlodipine Besylate homogeneity index 88.622% is so this drug may be 
suitable for direct compression by SeDeM. 
 
Table No: 8.7A Sedem Method To API In Amlodipine Besylate Powder Form      
Calculation  
 
INCIDENCE 
 
PARAMETER 
 
ACCEPTABLE  
RANGE 
 
 
Radius(r) 
 
 
Mean 
incidence 
 
 
Dimension 
 
Bulk density 0 - 1g/ml 3.1  
3.8 
Tapped density 0 – 1g/ml 4.5 
 
Compressibility 
Inter – particle porosity 0 – 1.2 8.073  
 
6.80 
Carr index 0 – 50(%) 6.222 
Cohesion index 0 – 200 (N) 6.1 
 
Flowability 
/powder flow 
 
Hausner ratio 3 – 1 7.74  
 
4.63 
Angle of repose 50 – 0 (0˚) 3.156 
Power flow 20 – 0 (S) 3 
 
Lubricity/ 
Stability 
 
Loss on drying 0 – 10(%) 12  
6.53 hygroscopicity 20 – 0 (%) 0.5 
 
Lubricity/dosage 
Particles <50µ 50 – 0(%) 7.08  
4.08 Homogeneity index 0 – 2 X 10 – 2 1.080 
Parametric profile index (mean r of all parameters) 5.213 
Good compression index (IGC) 6.80 
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 Dimension = 3.8 
 Compressibility = 6.80 
 Flowability /powder flow = 4.63 
 Lubricity/ Stability  = 6.53 
 
 
Figure: 8.7A Sedem Diagram Of Amlodipine Besylate Formulation 
Parametric profile index = 5.68 
Good compression index (IGC) = 6.44 
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Evaluation of the Amlodipine Besylate Tablet 
Weight Variation: 
             Average weight – Individual weight  
% Weight Variation =       X 100 
                                          Average weight  
 
                                = 3.02/20 
                  Aveage weight = 0.151mg   
Table No: 8.7B Weight Variation of the Amlodipine Besylate Tablet 
S.No Tablet Weight % Deviation 
1. 0.15 100 
2. 0.15 100 
3. 0.16 104.8 
4. 0.15 100 
5. 0.15 100 
6. 0.16 104.8 
7. 0.15 100 
8. 0.16 104.8 
9. 0.15 100 
10. 0.15 100 
11. 0.14 96.7 
12. 0.15 100 
13. 0.16 104.8 
14. 0.14 96.7 
15. 0.15 100 
16. 0.15 100 
17. 0.15 100 
18. 0.15 100 
19. 0.15 100 
20. 0.15 100 
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Friability: 
            Initial weight – Final weight  
% Friability=         X 100 
                           Initial weight 
 
            Initial wt.of tablet (20)                             = 3.02g 
Weighed of 20 tablet after friabilation        = 2.07g 
                                           Wt.loss         =3 02-2.76 
                                                                          = 0.26g 
Hardness: 
        Table No: 8.7C Hardness of the Amlodipine Besylate Tablet 
S.No Hardness kg/cm2 
1. 1.2 
2. 1.2 
3. 1.6 
4. 1.4 
5. 1.2 
6. 1.4 
7. 1.6 
8. 1.6 
9. 1.2 
10. 1.2 
 
 Average hardness = 1.22kg/cm2 
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Table No: 8.7d Dissolution of the Amlodipine Besylate Tablet 
S.No Time(min) Absorbance % Drug release 
1. 5 0.039 59.76 
2. 10 0.042 64.26 
3. 15 0.045 68.94 
4. 20 0.049 75.06 
5. 25 0.054 82.62 
6. 30 0.055 84.24 
 
OLMESARTAN MEDOXOMIL: 
Bulk Density (Da): 
                                                   Mass of the powder 
 LBD (Loose Bulk Density) = ---------------------------------  
                                                         Bulk volume 
  
                                                 10 
                                            = --------- 
                                                 19 
 
                                           = 0.53 gm/ml 
 
The acceptable range of Bulk density is 0 - 1g/ml in my study Olmesartan 
Medoxomil bulk density range is 0.53 gm/ml so this drug is made suitable for direct 
compression by SeDeM 
 
Tapped density (Dc): 
 
                       Mass of the powder 
Tapped density = ------------------------------ 
                                  Tapped volume 
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                     10 
                         = --------- 
                              13 
 
                        = 0.77gm/ml 
The acceptable range of Tapped density is 0 – 1g/ml in study Olmesartan 
Medoxomil Tapped density range is 0.77gm/ml so this drug is allowed  suitable for 
direct compression by SeDeM 
 
 
Average bulk density: 
 
                                                           Da + Dc 
Average bulk density= ---------------- 
                                                               2 
                                                           0.53 + 0.77 
                                                       = ------------------ 
                                                                2 
                                                   = 0.65 gm/ml 
 
Inter Particle Porosity (Ie): 
  
                                                        Da 
 Inter particle Porosity = 1 -     -------------------- 
        Dc 
  
     = 1 – (0.53/0.77) 
                               Porosity = 1- 0.6883 
                          = 0.3117 
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The acceptable range of Inter Particle Porosity is 0 – 1.2 in my study 
Olmesartan Medoxomil Inter Particle Porosity range is 0.3117 so this drug is suitable 
for direct compression by SeDeM 
 
Carr,s Index (Ic): 
         (Dc – Da) 
Ic = --------------- x 100 
                 Dc 
 
                 0.77 – 0.53 
            = ----------------- x 100 
                    0.77 
 
            =0.3116883 x 100 
 
                                 = 31.168% 
The acceptable range of Carr Index is 0 – 50 % in my study Olmesartan 
Medoxomil Carr Index range is 31.168% so this drug is passible to suitable for direct 
compression by SeDeM. 
 
Cohesion Index (Icd): 
 
The acceptable range of Cohesion Index is 0 – 200N Olmesartan Medoxomil 
Cohesion Index is 1N. It allows the drug formulate suitable for direct compression by 
SeDeM. 
Hausner’s ratio: 
                                       Dc 
Hausner’s ratio (IH) = --------------- 
                                      Da 
 
                                 0.77 
                       = -------------    
                                      0.53           
 
                               = 1.452 
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When t is the tapped density and d is bulk density. Lower H(<1.25) indicates 
better flow properties than higher ones(>1.25). The acceptable range of Hausner’s 
ratio is 1 – 3 in my study Olmesartan Medoxomil Hausner’s ratio is 1.452 hence, this 
drug is made suitable for direct compression by SeDeM. 
 
Angle of Repose (θ) 
tanθ = h/r θ = tan-1 (h/r) 
 
Table No: 8.8 ANGLE OF REPOSE OF OLMESARTAN MEDOXOMIL DRUG BY 
FUNNEL METHOD 
 
Name 
of 
the drug 
powder 
 
Height 
of the 
pile 
(h) cm 
 
Diameter 
of the 
pile (d) 
cm 
 
Radius of 
the pile (r) 
cm 
 
h/r 
 
Q= tan-1 
(h/r) 
 
Average 
 
Olmesartan 
Medoxomil 
 
2.2 
 
2.1 
 
2.2 
 
5.8 
 
6 
 
5.9 
 
2.9 
 
3 
 
3 
 
0.76 
 
0.7 
 
0.73 
 
37˚.23’ 
 
34˚.99’ 
 
36˚.12’ 
 
 
 
34˚.99’ 
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ANGLE OF REPOSE OF OLMESARTAN MEDOXOMIL DRUG BY FUNNEL 
METHOD GRAPH: 
 
1. h = 2.2 cm 
             d = 5.8 cm 
             r = 2.9 cm 
 
2. h = 2.1 cm 
             d = 6 cm 
              r = 3 cm 
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3. h = 2.2 cm 
             d = 5.9 cm 
              r = 3 cm 
 
 
The Olmesartan Medoxomil powder is a possible flow. The acceptable range 
of Angle of Repose is 0 – 50 ˚ in my study Olmesartan Medoxomil powder Angle of 
Repose by funnel method is 34˚.99’ so this drug is suitable for direct compression by 
SeDeM. 
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OPEN END CYLINDER TECHNIQUES: 
Table No: 8.9Angle of Repose of Olmesartan Medoxomil Drug By Open End 
Cylinder Method 
 
Name 
of 
the drug 
powder 
 
Height 
of the 
pile 
(h) cm 
 
Diameter 
of the 
pile (d) 
cm 
 
Radius of 
the pile (r) 
cm 
 
h/r 
 
Ɵ= tan-1 
(h/r) 
 
Average 
 
 
Olmesartan 
medoxomil 
 
2 
 
2.1 
 
2.1 
 
6.1 
 
6 
 
5.9 
 
 
 
3.1 
 
3 
 
3 
 
0.64 
 
0.7 
 
0.7 
 
32˚.61’ 
 
34˚.99’ 
 
34˚.99’ 
 
 
 
34˚.99’ 
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ANGLE OF REPOSE OF OLMESARTAN MEDOXOMIL DRUG OPEN END 
CYLINDER METHOD GRAPH: 
1.   h = 2 cm 
             d = 6.1 cm 
              r = 3.1 cm 
 
2. h = 2.1 cm 
             d = 6 cm 
              r = 3 cm 
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3. h = 2.1 cm 
              d = 5.9 cm 
               r = 3 cm 
 
 
 
 
 The Olmesartan Medoxomil drug is a possible flow. The acceptable 
range of Angle of Repose is 0 – 50 ˚ in my study Olmesartan Medoxomil drug Angle 
of Repose by open end cylinder method is 34˚.99’ so this drug is potentially suitable 
for direct compression by SeDeM. 
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Flowability (t″) 
Open End Cylinder Method 
 
Sample = Olmesartan Medoxomil 
 
Table: 8.10 Flow Ability of Olmesartan Medoxomil Drug Using Open End 
Cylinder Method 
S.NO PASSING TIME 
(Sec) 
1.  2 sec 
2. 3 sec 
3. 2 sec 
 
                                        Average mean = (2+3+2)/3 x 10 
 
= 3.5sec 
The acceptable range of Flowability is 0 – 20sec in my study Olmesartan 
Medoxomil Flowability is 3.5sec so this drug is suitable for direct compression by 
SeDeM. 
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LOSS ON DRYING: 
  Loss on drying = Initial weight of the drug – Final weight of the drug X 100 
 
                          = 10 – 9.83 X 100 
 
                          = 0.17 X 100 
 
                          = 17% 
 
The acceptable range of loss on drying is 0 – 10(%) in the present study 
Olmesartan Medoxomil loss on drying is 17%, as a result, this drug is may be 
suitable for direct compression by SeDeM. 
 
HYGROSCOPICITY (%H): 
  
Hygroscopicity = (Final weight of the drug – initial weight of the drug) X 100 
 
                        = 10.12 -10 X 100 
                        = 0.12 X 100 
                        = 12% 
The acceptable range of hygroscopicity is 0 – 20% in my study Olmesartan 
Medoxomil hygroscopicity is 12% so this drug is fitting for direct compression by 
SeDeM. 
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Particle Size (%Pf) Of Olmesartan Medoxomil Drug by Eye Piece Micrometer 
Calibration Of Eye Piece Micrometer:- 
                                                                     No of division of stage micrometer 
One division of Eyepiece micrometer =                                                               x 10µ 
                                                               No of division of eye – piece micrometer 
1. 5/4 x 10 = 12.5 
2. 10/8 x 10 = 12.5 
3. 15/12 x 10 = 12.5                       
 
One division of eyepiece micrometer = 12.5 µm 
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Table N0:8.11 Particle Size of Olmesartan Medoxomil by Eye Piece Micrometer 
S.NO 
EYE PIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
S.NO 
EYE PIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
1. 8 100 41. 14 175 
2. 10 125 42. 13 162.5 
3. 12 150 43. 12 150 
4. 8 100 44. 14 175 
5. 9 112.5 45. 13 162.5 
6. 11 137.5 46. 12 150 
7. 15 187.5 47. 11 137.5 
8. 12 150 48. 14 175 
9. 12 150 49. 15 187.5 
10. 15 187.5 50. 15 187.5 
11. 13 162.5 51. 15 187.5 
12. 18 225 52. 15 187.5 
13. 12 150 53. 14 175 
14. 15 187.5 54. 11 137.5 
15. 13 162.5 55. 12 150 
16. 15 187.5 56. 13 162.5 
17. 11 137.5 57. 14 175 
18. 16 200 58. 11 137.5 
19. 12 150 59. 11 137.5 
20. 17 212.5 60. 12 150 
21. 11 137.5 61. 15 187.5 
22. 14 175 62. 16 200 
23. 12 150 63. 14 175 
24. 15 187.5 64. 15 187.5 
25. 11 137.5 65. 11 137.5 
26. 11 137.5 66. 15 187.5 
27. 11 137.5 67. 13 162.5 
28. 12 150 68. 14 175 
29. 15 187.5 69. 11 137.5 
30. 16 200 70. 14 175 
31. 14 175 71. 13 162.5 
32. 12 150 72. 12 150 
33. 13 162.5 73. 14 175 
34. 14 175 74. 8 100 
35. 11 137.5 75. 10 125 
36. 15 187.5 76. 12 150 
37. 13 162.5 77. 8 100 
38. 15 187.5 78. 9 112.5 
39. 11 137.5 79. 11 137.5 
40. 15 187.5 80. 15 187.5 
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S.NO 
EYE PIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
S.NO 
EYE PIECE 
DIVISION 
PARTICLE 
SIZE (µm) 
81. 12 187.5 91. 16 137.5 
82. 12 150 92. 12 200 
83. 15 150 93. 17 150 
84. 13 187.5 94. 11 212.5 
85. 18 162.5 95. 14 137.5 
86. 12 225 96. 12 175 
87. 15 150 97. 15 150 
88. 13 187.5 98. 11 187.5 
89. 15 162.5 99. 15 137.5 
90. 11 187.5 100. 11 187.5 
 
 
Table No: 8.12 particles Size of Olmesartan Medoxomil 
S.NO AVERAGE SIZE MIDPOINT 
NO.OF PARTICLES 
PRESENT 
1. 0 – 50 25 - 
2. 50 – 100 75 4 
3. 100 – 150 175 42 
4. 150 – 200 175 50 
5. 200 – 250 225 4 
6. 250 – 300 275 - 
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Figure No: 8.12 PARTICLE SIZE DISTRIBUTION OF OLMESARTAN 
MEDOXOMIL 
The Average Olmesartan Medoxomil particle size is160.5µm, and my study 
drug particle mean diameter is 160.5µm, with  Total range is 0-300µ  and Size range 
of which maximum particle exist is 150-200µm with Mode diameter of 175µ, 187.5µ, 
162.5µ, 200µ.The acceptable range of particle size is 50µ in my study Olmesartan 
Medoxomil particle size by eye piece micrometer is 160.5µso this drug may be 
suitable for direct compression by SeDeM. 
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Table No: 8.13 Determination of Olmesartan Medoxomil Drug Particle Size by 
Sieving Method 
 
 
S.NO 
 
Sieve no 
 
Sieve  
opening 
(µ) 
 
Mean size 
opening 
(µ) 
 
Weight of the 
Drug retain 
(gms) 
 
Percentage 
weight of 
the Drug 
 
Weight 
size 
1. 44 355 355 0.52 x 10 = 5.2 5.2% 846 
2. 44/60 355/250 302.5 0.95 x 10 = 9.5 9.5% 2873.75 
3. 60/80 250/177 213.5 1.85 x 10 = 
18.5 
18.5% 3949.75 
4. 80 177 177 6.51 x 10 = 
65.1 
65.1 % 11522.7 
5. Total Weight of the Drug Percentage & Weigh Size 98.3% 191.922 
 
Weigh size = Arithmetic mean size of opening x percentage of weight of the 
             powder obtained 
 
       Weigh size              19192.2 
              Arithmetic mean =-------------------- = ---------------- = 191.922µ 
             100                       100 
Percentage under size (adding up to weight size) 
Percentage oversize (From the 100 subtract the values) 
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TABLE No: 8.14 OLMESARTAN MEDOXOMIL DRUG PARTICLE SIZE BY 
SIEVING METHOD 
 
S.NO 
WEIGHT OF 
DRUG  RETAINED 
(gm) 
PARTICLE 
SIZE OPENING 
() 
WEIGHT OF 
UNDER SIZE 
WEIGHT OF 
OVERSIZE 
 
1. 
2. 
3. 
4. 
 
 
5.2 
9.5 
18.5 
65.1 
 
355 
302.5 
213.5 
177 
 
5.2 
14.7 
33.2 
98.3 
 
94.80 
85.3 
66.8 
1.7 
 
 
 
 The arithmetic mean of olmesartan Medoxomil is 191.922µ 
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HOMOGENEITYINDEX (Iθ): 
                                                       Fm 
Iθ = ----------------------------------------------------------------------------------------------------------- 
         100+(dm-dm-1)Fm-1+(dm+1-dm)Fm+1+(dm-dm-2)Fm-2+(dm+2-dm)Fm+2 
            +(dm-dm-n)Fm-n+(dm+n-dm)Fm+n 
 
39.50 
                    =  ------------------------ 
                               21003.61 
                  =0.001880629% 
 
Table No: 8.15 Homogeneity Index of Olmesartan Medoxomil 
Sieve (mm) Corresponding 
Average of 
the diameter 
of the 
fraction 
Corresponding 
diameter 
(dm……dm± n) 
Difference dm 
with the 
major 
component 
0.355 – 0.850 Fm + 2 18.46 dm + 2 21.04 
0.250 – 0.355 Fm + 1 28.74 dm + 1 10.76 
0.177 – 0.250 Fm 39.50 dm 0 
0.149 – 0.177 Fm – 1 115.22 dm – 1 75.72 
<0.149 Fm – 2 0 dm – 2 39.5 
 
 
Olmesartanmedoxomil homogeneity index158.395% is, therefore, this drug 
may be suitable for direct compression by SeDeM. 
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Table No: 8.16 Olmesartan Medoxomil and Amlodipine Besylate Compared To 
Acceptable Range 
 
INCIDENCE 
 
PARAMETER 
 
ACCEPTABLE 
RANGE 
 
OLMESARTAN 
MEDOXOMIL 
 
AMLODIPINE 
BESYLATE 
 
Dimension 
 
Bulk density 0 - 1g/ml 0.53 g/ml 0.3 g/ml 
Tapped 
density 
0 – 1g/ml 0.77 g/ml 0.45g/ml 
 
Compressibility 
Inter – particle 
porosity 
0 – 1.2 0.3111 gm/ml 
 
0.312gm/ml 
Carr index 0 – 50(%) 31.17% 31.11% 
Cohesion 
index 
0 – 200 (N) 1.22N 1N 
 
Flowability 
/powder flow 
 
Hausner ratio 3 – 1 1.452 1.451 
Angle of 
repose 
50 – 0 (0˚) 34˚ 99’ 34˚99’ 
Power flow 20 – 0 (S) 3.5sec 3 sec 
 
Lubricity/ 
Stability 
 
Loss on drying 0 – 10(%) 17% 22% 
higroscopicity 20 – 0 (%) 12% 19% 
 
Lubricity/dosage 
Particles <50µ 50 – 0(%) 98.3% 85.4% 
Homogeneity 
index 
0 – 2 X 10 – 2 88.622 
 
158.395 
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Table No: 8.17 Sedem Method to API in Olmesartan Medoxomil Drug Form      
Calculation  
  
 
 
 
 
 
 
 
 
 
INCIDENCE 
 
PARAMETER 
 
ACCEPTABLE  
RANGE 
 
 
Radius(r) 
 
 
Mean 
incidence 
 
 
Dimension 
Bulk density 0 - 1g/ml 5.3 6.5 
Tapped density 0 – 1g/ml 7.7 
 
Compressibility 
Inter – particle porosity 0 – 1.2 8.074  
6.436 Carr index 0 – 50(%) 6.234 
Cohesion index 0 – 200 (N) 5 
 
Flowability 
/powder flow 
Hausner ratio 3 – 1 7.76  
4.754 Angle of repose 50 – 0 (0˚) 3.002 
Power flow 20 – 0 (S) 3.5 
Lubricity/ 
Stability 
Loss on drying 0 – 10(%) 7  
5.5 higroscopicity 20 – 0 (%) 4 
 
Lubricity/dosage 
Particles <50µ 50 – 0(%) 9.66  
5.30 Homogeneity index 0 – 2 X 10 – 2 0.940 
Parametric profile index (mean r of all parameters) 5.68 
Good compression index (IGC) 6.44 
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 Dimension = 6.5 
 Compressibility = 6.436 
 Flow ability /powder flow = 4.754 
 Lubricity/ Stability  = 5.5 
 
Figure: 8.17 SeDeM diagram of olmesartan medoxomil formulation 
Parametric profile index = 5.68 
Good compression index (IGC) = 6.44 
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Evaluation of the Olmesartan Medoxomil Tablet 
Weight Variation: 
 
                 Average weight – Individual weight 
% Weight Variation =        X 100 
                                           Average weight  
 
                                = 3.12/20 
                  Average weight = 0.156mg 
Table No: 8.18 Weight Variation of the Olmesartan Medoxomil Tablet 
S.No Tablet Weight % Deviation 
1. 0.15 100 
2. 0.16 104 
3. 0.13 92 
4. 0.16 104 
5. 0.16 104 
6. 0.16 104 
7. 0.15 100 
8. 0.16 104 
9. 0.16 104 
10. 0.16 104 
11. 0.16 104 
12. 0.16 104 
13. 0.15 100 
14. 0.15 100 
15. 0.15 100 
16. 0.16 104 
17. 0.15 100 
18. 0.17 108 
19. 0.17 108 
20. 0.15 104 
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Friability: 
    Initial weight – Final weight  
% Friability =     X 100 
                          Initial weight 
 
            Initial wt.of Tablet(20)                             =3.15g 
Weighed of 20 tablet after friabilation      =2.95g 
                                           Wt.loss           =3.15-2.95 
                                                                             =0.2g 
Hardness: 
       Table No: 8.18 Hardness of the Olmesartan Medoxomil Tablet 
S.No Hardness kg/cm2 
1. 1 
2. 1.4 
3. 1 
4. 1.2 
5. 1 
6. 1.4 
7. 1.2 
8. 1 
9. 1.2 
10. 1 
 
 Average hardness = 1kg/cm2 
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Table No: 8.19 Dissolution Of The Olmesartan Medoxomil Tablet. 
S.No Time(min) Absorbance % Drug Release 
1. 5 0.207 51.84 
2. 10 0.211 52.92 
3. 15 0.218 54.63 
4. 20 0.221 55.35 
5. 25 0.228 57.15 
6. 30 0.236 59.13 
 
Scanning Electron Microscopy (olmesartan Medoxomil and Amlodipine 
Besylate) 
The morphological appearance of the electrospun fiber and that fiber were 
investigated by a ZEISS-5200 scanning electron microscope (SEM), operating at an 
acceleration voltage of 20 KV. For each sample, the average diameter of the 
individual fibers was measured from multiple SEM images at the magnification of 2.0 
KX by semaphore 4.0 software. The result of each sample was reported as an 
average value from at least three measurements. A Lloyd LRX universal tester was 
used to determine the mechanical integrity of some of the as-spun fibers. The gauge 
length and the crosshead speed were 10 µm per minute, respectively. 
The percentage of particle size is measured generally in sieving method 
according to the pharmacopeial standard requirement, but I was trying to measure 
the particle size and distribution of particle size in within the tablet as using SEM. 
These are accurate measure method for the particle size analysis. According to SEM 
method results found out the <10µm particles present in the prepared tablet, that 
was a very crucial factor for sedem diagram direct compression method. This result 
gave the precious result of homogeneity index, this index was an important factor for 
during drug disintegration and dissolution of tablet dosage form in this method of 
manufacturing. The amlodipine Besylate tablet drug and excipient particle size 
distribution is 5.5µm which gives the theoretical QBD designing conclusion and has 
been giving significant dissolution of tablet and the same thing also of olmesartan 
Medoxomil tablet. So from this SEM results, these prepared tablets were fulfilled the 
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sedem diagram one of a parameter of particle size and homogeneity. The particles 
are also having lubricity energy, because they under processing of direct 
compression lubricity values has been detected, which results in poor particle size 
distribution, weight variation, and content uniformity of tablet dosage form. The 
above parameters are results to below the compendial limit which is the dosage 
forms has been unqualified for the human use, so from this results in these prepared 
tablets meet the compendia level for IP 2016. 
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                                          CONCLUSION 
  Now we developed a unique methodology for the preformulation and powder 
substance description. This process facilitates a study on the design and 
development of formulations for the manufacture of tablets by direct compression. 
The SeDeM specialist method is a helpful tool since, in adding up to allow for the 
type of mechanism, it also provide a recommendation on the intrinsic property, such 
as the character and morphology of the particles. We recommend that given the 
correctness of the in sequence provide by this method, formulations determination 
have a higher possibility of successfully compressed. This method characterizes the 
individual mechanism of a formulation and applies a mathematical testing to find out 
the accurate amount of both in the finishing formulation. The formulation provides will 
be suitable for direct compression. This modern method offers various advantages 
from a production view. In adding to creature faster than other technique, it is 
necessary as it reduces the number of steps at some stage in the manufacturing 
process., SeDeM has the benefit of providing a formulation with the least amount of 
excipients as it combine the API by only one excipient and the standard formula of, 
consequently avoiding the used of unnecessary excipients, such as diluents, binder, 
and agglutinants. The information given by the SeDeM system contributes to an 
excellence by Design Development. Subsequently, this new tool is steady with the 
current requirements of narrow health establishment such as the FDA and ICH. 
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